Sophiris, Stock Sliding After Cancer Drug Data, Still Plans Phase 3
Xconomy
DECEMBER 17, 2018
The news sent the San Diego, CA-based biotech’s stock plunging 40 percent. Sophiris Bio said Monday that 10 patients who were administered its experimental prostate cancer drug a second time didn’t see any additional benefit.
Let's personalize your content